For example, up to ~30%–40% of ATCs harbor the BRAF V600E mutation, and dual BRAF/MEK inhibition (dabrafenib plus trametinib) has achieved objective responses in clinical trials [11, 12]. This evidence concerns the gene BRAF and Ehlers-Danlos syndrome, musculocontractural type.